Displaying 2501 - 2520 of 4737
FTC Approves Application from ZF Friedrichshafen AG and TRW Automotive Holdings Corp. to Divest TRW’s Linkage and Suspension Business in North America and Europe
ZF Friedrichshafen and TRW Automotive, In the Matter of
Two of the world’s largest auto parts suppliers, ZF Friedrichshafen AG and TRW Automotive Holdings Corp., agreed to divest TRW's linkage and suspension business in North America and Europe, to settle FTC charges that their proposed $12.4 billion merger would likely harm competition in the North American market for heavy vehicle tie rods. Under the consent agreement, the combined company is required to divest TRW’s North American and European linkage and suspension business for heavy and light vehicles (which includes heavy vehicle tie rods). The business includes five manufacturing plants in Michigan, Canada, the Czech Republic, and Germany, and leased space in a research and development lab in Germany. At the divestiture buyer’s request, ZF must provide transition services for logistical and administrative support as well as transitional supply agreements for key manufacturing inputs needed to fulfill existing customer contracts.
Third Point Funds Agree to Settle FTC Charges that They Violated U.S. Premerger Notification Requirements
Dissenting Statement of Commissioners Maureen K. Ohlhausen and Joshua D. Wright - In the Matter of Third Point
FTC Requires Pfizer Inc. to Sell Rights to Four Products as a Condition of Acquiring Hospira, Inc.
FTC Approves Final Order Preserving Competition in U.S. Markets for Three Orthopedic Medical Products
Zimmer Holdings, Inc. / Biomet, Inc., In the Matter of
Medical device company Zimmer Holdings, Inc. agreed to divest U.S. rights and assets related to unicondylar knee implants, total elbow implants, and bone cement in order to settle FTC charges that its proposed $13.35 billion acquisition of Biomet Inc. is anticompetitive. According to the complaint, Zimmer and Biomet are two of the only three substantial competitors in the U.S. markets for unicondylar knee implants and total elbow implants, and two of only four significant competitors in the U.S. market for bone cement. The order requires Zimmer to divest to Smith & Nephew the U.S. intellectual property, manufacturing technology, and existing inventory relating to its unicondylar knee implant, and to provide transitional services to help them establish manufacturing capabilities and secure necessary FDA approvals. The order also requires Biomet to divest to DJO the U.S. intellectual property, manufacturing technology, and existing inventory relating to its total elbow implant and bone cement products, and it facilitates DJO’s hiring of the Biomet sales representatives and other staff who work with these products.
Pharmaceutical Companies Settle FTC Charges of an Illegal Agreement not to Compete, which Resulted in Higher Prices for Generic Version of ADHD Drug
1508003 Informal Interpretation
FTC Commissioner Joshua D. Wright to Resign
1508004 Informal Interpretation
Daniel Bock, Jr., Plaintiff-Appellee, v. Pressler & Pressler, LLP, Defendant-Appellant
FTC Issues Statement of Principles Regarding Enforcement of FTC Act as a Competition Statute
Federal Trade Commission (Bureau of Competition) and Department of Justice (Antitrust Division): Hart-Scott-Rodino Annual Report: Fiscal Year 2014: Section 7A of the Clayton Act, 15 U.S.C. 18a (The Hart-Scott-Rodino Antitrust Improvements Act of 1976)
FTC Approves Fiscal Year 2014 HSR Premerger Notification Report
1508001 Informal Interpretation
Displaying 2501 - 2520 of 4737